Background: Recombinant human interleukin-11 (rhIL-11) is a cytokine produced by recombinant
DNA technology and used clinically to treat chemotherapy-induced thrombocytopenia. A
Size Exclusion Liquid Chromatography (SE-LC) method was validated to assess the content/potency of
Methods: A BioSep-SEC-S2000 column (300 mm × 7.8 mm i.d.) maintained at 30°C was used. The
mobile phase was composed of 0.02 M 2-(N-morpholino)ethanesulfonic acid and 0.5 M sodium chloride
buffer, pH 6.0, run isocratically at a flow rate of 0.9 mL min-1, with detection by Photodiode Array
(PDA) detector set at 220 nm.
Results: Chromatographic separation was obtained with a retention time of 8.12 min, and the stabilityindicating
capability, and specificity was demonstrated. The method was linear over the concentration
range of 1.0–200 µg mL-1 (r2= 0.9996) and the Detection Limit (DL) and Quantitation Limit (QL) were
0.23 µg mL-1 and 1.0 µg mL-1, respectively. The accuracy was 99.81% with bias lower than 0.43%.
Moreover, method validation showed acceptable results for precision and robustness.
Conclusion: The method was applied to the assessment of rhIL-11 and Higher Molecular Weight forms
(HMW) in biopharmaceutical formulations, and the results of content/potencies were correlated to those
of a validated Reversed-Phase Liquid Chromatography (RP-LC) and a Capillary Zone Electrophoresis
(CZE) methods, showing non-significant differences (p> 0.05). The proposed method and the correlation
studies contribute to monitor stability, improve the quality control and ensure the batch-to-batch
consistency of the biotherapeutics.